Joel F. Farley, R.Ph., Ph.D. is a pharmacist and pharmaceutical outcomes researcher specializing in the evaluation of pharmaceutical policy changes on patients with chronic health conditions.  His primary research focus is designed to ensure proper implementation of managed care policies in patients with chronic health conditions while safeguarding accessibility to medications for patients who need them.

Dr. Farley has expertise analyzing claims data from secondary data sources.  His prior research has involved the use of data collected from publicly available surveys such as the Medical Expenditure Panel Survey and the Medicare Current Beneficiary Survey, private health insurance claims provided from individual insurers including United Health Care and Blue Cross Blue Shield of North Carolina, and health claims data collected from multiple insurers such as Market Scan’s Commercial Claims and Encounters (CCAE) data.  Dr. Farley has extensive experience working with Medicaid claims data. Past projects have assessed the impact of Medicaid prescription managed care policies on economic and clinical outcomes in patients with mental illness using Medicaid Analytical Extract data from 13 different state Medicaid programs.  Dr. Farley has published several papers related to prescription management of osteoporosis.  These studies are concentrated around ensuring access to anti-osteoporosis medications in patients vulnerable to fracture.

He has served as a consultant to Blue Cross Blue Shield of North Carolina to support the evaluation of a copayment waiver for medications used to treat chronic diseases.  His assistance in this collaboration was instrumental in the design of a compliance algorithm to track changes in medication adherence and on the evaluation of the impact of this program on medication adherence and the cost of treatment for diabetes, hypertension, congestive heart failure, and hyperlipidemia.  In addition, he is currently collaborating with the AccessCare of North Carolina to evaluate the effect of implementing a medication registry entitled A+KIDS (Antipsychotics – Keeping it Documented for Safety) on patterns of treatment for antipsychotic medications in children and adolescents in the North Carolina Medicaid Program.

Dr. Farley’s research has been funded by grants and contracts from the Robert Wood Johnson Foundation, The American Health-System Pharmacy Foundation, the Agency for Health Care Research and Quality, the Pfizer Foundation, Blue Cross Blue Shield of North Carolina, and North Carolina Community Care Networks.

Teaching Statement:
As a pharmacist and academician, I am dedicated to instructing the next generation of pharmacy leaders as they transition into independent clinicians and researchers.

Teaching Philosophy
My overall teaching philosophy is based on the belief that students learn and retain information most effectively when they apply knowledge through active participation.  My lesson plans focus not only on the provision of conceptual and factual information, but also on higher levels of problem solving through active learning exercises.  Within the professional pharmacy program, I engage students in active learning by guiding students through common cases that occur in pharmacy settings.  It is my belief that by working through cases in a structured classroom setting, students will be well prepared to handle similar encounters when they begin their professional practices.  Active learning techniques commonly used within the classroom include individual reflection, group problem solving, and think-pair-share exercises.  In addition, key concepts are reinforced through written assignments which serve as the basis for evaluating student comprehension.

Active learning is also encouraged within the graduate level courses I teach.  However, the learning process is tailored to encourage graduate students to become effective independent researchers.  Students are required to research topic areas independently and share their research with other students and faculty through oral presentation and written assignments.  These active learning activities are designed not only to improve students’ understanding of the topic area being researched, but also to improve oral and written communication skills which are critical to becoming an effective independent researcher.

DPOP 806 (Course Coordinator)

Pharmaceutical Policy
This course examines policies that influence pharmacy. Structured methods of policy analysis are examined and used to assess theoretic and analytic applications for evaluating pharmaceutical policy.

PHCY 431 (Instructor)
Health Systems
Introduces first-year students to the U.S. health care system and different practice settings that pharmacists practice. Topics covered include: the history of the U.S. health care system, Medicaid, Medicare, private health insurance, pharmacoeconomics, drug policy, mental health pharmacy, the pharmaceutical industry, community health centers, public health pharmacy, hospital pharmacy, and community pharmacy.

PHCY 433 (Instructor)
Drug Literature Analysis and Interpretation
Provides students with a working knowledge of the concepts and methods of clinical drug trials. In addition the course reviews the principles of drug study design and biostatistics. The course blends concepts and principles with discussion of clinically-important articles from the biomedical literature. This course will add to students’ competencies in identifying, analyzing and interpreting literature and assist students in their application of that literature into clinical practice.

  • Mrudula Borse – Thesis: TBD. (Expected graduation May, 2016)
  • Andrew Roberts – Thesis: Locked In – Evaluating a North Carolina Medicaid Controlled Substance Policy. (Expected graduation May, 2015)
  • Rishi Desai (co-adviser with Jaya Rao) – Thesis: TNF-alpha inhibitor treatment and the risk of atherosclerotic events in patients with rheumatoid arthritis. (Completed March 28, 2013)
  • Aaron Katz – Thesis: “Use, Effectiveness, and Safety of bevacizumab in older adults with advanced non-small cell lung cancer.” (Completed November 29, 2012)
  • Jonas Daugherty – Thesis: The impact of pharmaceutical manufacturer coupons on medication adherence, persistence, and cost among lipid lowering agents. (Expected Graduation May 2015)
  • David Wei – Thesis: “Economic Evaluation of Biological Therapy Use among Patients with Crohn’s Disease.” (Completed June, 28 2012)
  • Chi-Chuan (Emma) Wang – Thesis: “The Effect of Adjunctive Psychotherapy on Health Related Outcomes among Patients with Schizophrenia.” (Completed May, 2011)


7/01/2013 – 06/30/2015
National Institutes of Health – National Institute on Aging
Should the Elderly Have Lower Dose of ACE Inhibitors for Secondary Prevention after AMI?
This retrospective observational cohort study will compare the real-world treatment effectiveness and safety of the established RCT doses of ACE inhibitors post AMI versus lower doses in the elderly.
Role: Co-investigator
Total direct UNC costs: $263,720
Percent effort: 8%

CDC-NCIPC U01 20120502

10/01/2012 – 09/30/2014
National Center for Injury Prevention and Control (NCIPC)
Change in Opioid Use and Overdose After a Medicaid Lock-in Program
This evaluation will determine the effectiveness of a Medicaid lock-in program designed to reduce misuse of controlled substance prescription drugs.
Role: Co-investigator
Total direct UNC costs: $283,408
Percent effort: 5%

NC TraCS Institute

06/01/2012 – 05/30/2013
North Carolina Translational and Clinical Science (TraCS) Institute Grant
A Programmatic Description of the UNC Charity Care Pharmacy Assistance Program
This study will examine a population of patients receiving prescriptions through the UNC pharmacy assistance program focusing on the population being served, the prescription services utilized, and the effect of the program on medication adherence and health service utilization.
Role: Principal Investigator
Total direct UNC costs: $35,891
Percent effort: 0%

Contract (Farley)

7/1/2013 – 6/30/2014
North Carolina Community Care Networks
A+KIDS – Antipsychotics in KIDS (Keeping it Documented for Safety) Extension
The major goal of this contract is to evaluate the effect of a pediatric antipsychotic registry on metabolic screening and antipsychotic utilization in the NC Medicaid population.
Role: Principal Investigator
Total direct UNC costs: $68,885
Percent effort: 20%

Contract (Farley)

1/1/2013 – 6/30/2013
North Carolina Community Care Networks
Report of the CheckMeds Program
The major goal of this contract was to evaluate the CheckMeds program in North Carolina to provide recommendations to the Office of Rural Health related to optimal data capture and reporting for the purpose of ongoing operations and formal evaluation capabilities.
Role: Principal Investigator
Total direct UNC costs: $14,881
Percent effort: 20%

  1. Farley, Joel F. (2014) “Other Observational Study Designs” (Chapter 6) in Principles of Research Design and Drug Literature Evaluation by Rajender R. Aparasu (Editor) and John P. Bentley (Editor), Jones and Bartlett. (In press)
  2. Domino, Marisa Elena and Farley, Joel F. (2010). “Economic Issues in Psychotropic Medication use.” (pp. 481-498) In Mental Health Services: A Public Health Perspective, Ed.3 by Bruce Lubotsky Levin (Editor), Kevin D. Hennessy (Editor), John Petrila (Editor), Oxford University Press, Oxford.
  1. Maciejewski ML, Wansink D, Lindquist JH, Parker JC, Farley, JF. (2014) “Value-Based Insurance Design Program In North Carolina Increased Medication Adherence But Was Not Cost Neutral” Health Affairs. 33(2):300-308.
  2. Daugherty JB, Maciejewski ML, Farley JF. (2013) “The impact of manufacturer coupons in the statin market.” Journal of Managed Care Pharmacy. 19(9):765-772. (PMID: 24156645)
  3. Lauffenburger JC, Balasubramanian A, Farley JF, Critchlow CW, O’Malley CD, Roth MT, Pate V, Brookhart MA. (2013) “Completeness of prescription information in US commercial claims databases”. Pharmacoepidemiology and Drug Safety. 22(8):899-906. (PMID: 23696101)
  4. Wu, CH, Wang CC, Katz AJ, Farley JF. (2013) “National trends of psychotropic medication use among patients diagnosed with anxiety disorders: Results from Medical Expenditure Panel Survey 2004-2009” Journal of Anxiety Disorders. 27(2):163-170 (PMID: 23428605)
  5. Wang CC, Wei D, Farley JF. (2013) “Impact of monthly prescription cap on medication persistence among patients with hypertension.” Journal of Managed Care Pharmacy. 19(3):258-268. (PMID: 23537460)
  6. Farley JF, Weeks L, Wegner SE. (2013) “The A+KIDS Program” Psychiatric Services. 64(1): 98-99. (PMID: 23280465)
  7. Hansen RA, Maciejewski ML, Yu-Isenberg K, Farley JF. (2012) “Adherence to antipsychotics and cardiometabolic medication association with health care utilization and costs.” Psychiatric Services. 63(9):920-928 (PMID: 22706887)?)
  8. Farley JF, Hansen RA, Yu-Isenberg KS, Maciejewski ML. (2012) “Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions” The Primary Care Companion for CNS Disorders. Published online at (PMID: 23106028)
  9. Farley JF, Wansink D, Lindquist JH, Parker JC, Maciejewski ML. (2012) “Medication Adherence Changes following Value Based Insurance Design (VBID)” American Journal of Managed Care. 18(5):41-50. (PMID: 22694064)
  10.  Farley JF, Wang CC, Hansen RA, Voils CI, Maciejewski ML. (2011) “Continuity of Antipsychotic Medication Management for Medicaid Patients with Schizophrenia” Psychiatric Services. 62(7):747-752. (PMID: 21724787)
  11. Maciejewski ML, Farley JF, Parker J, Wansink D. (2010) “Copayment Reductions Generate Greater Medication Adherence in Targeted Patients” Health Affairs. 29(11):2002-8. (PMID: 21041739)
  12. Farley JF, Wang CC, Blalock SJ. (2010) The status of Ph.D. education in Economic, Social, and Administrative Sciences between 2005 and 2008. American Journal of Pharmacy Education. 74(7): Article 126. (PMID: 21088732)
  13. Farley JF. (2010) “Medicaid prescription cost containment and schizophrenia: a retrospective examination.” Medical Care. 48(5):440-447. (PMID: 20351586)
  14. Farley JF, Cline RR, Schommer JC, Hadsall RS, Nyman JA. (2008) “Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications”.  Clinical Therapeutics. 30(8):1524-1539. (PMID: 18803994)
  15. Farley JF, Blalock SJ, Cline RR. (2008) “Effect of the Women’s Health Initiative on prescription anti-osteoporosis medication utilization”. Osteoporosis International. 19(11):1603-1612. (PMID: 18373048)
  16. Farley JF, Devine JD, Hadsall RS.  (2007) “Professional implications of the expansion of pharmacy-based medical clinics”.  Journal of the American Pharmacists Association 47(3): 410-413. (PMID: 17510039)
  17. Farley JF, Cline RR, Gupta K. (2006) “Racial variation in antiresorptive medications use: results from the 2000 Medical Expenditure Panel Survey (MEPS)”. Osteoporosis International.  17(3): 395-404. (PMID: 16314982)
  18. Farley JF, Harley CR, Devine JW. (2006) “A comparison of comorbidity measurements to predict health expenditures.”  American Journal of Managed Care. 12(2): 110-117. (PMID: 16464140)

(Selected from more than 20 peer-reviewed podium and 25 peer-reviewed poster presentations)

  1. Roberts AW, Dusetzina SB, Farley JF. “Implications of Washout Period Duration in Incident User Study Designs in Commercially Insured Populations” American Pharmacists Association Annual Meeting, Orlando, FL, March 28-31, 2014.
  2. Desai RJ, Rao JK, Hansen RA, Maciejewski ML, Fang G, Farley JF. “Cardiovascular Diseases In Rheumatoid Arthritis: Can Early Treatment With Disease-Modifying Antirheumatic Drugs Alter The Risk”. American College of Rheumatology(ACR)/ Association of Rheumatology Health Professionals (ARHP) Annual Meeting. San Diego, CA, October, 27, 2013.
  3. Maciejewski ML, Hansen RA, Powers BJ, Sanders L, Farley JF, Voils CI, Sleath B. “Prescriber Continuity and Medication Adherence for Complex Patients” Academy Health 2013 Annual Research Meeting.  Baltimore MD, June 25, 2013.
  4. Ellis A, Dusetzina SB, Hansen RA, Gaynes B, Farley JF, Sturmer T. “Comparison of Propensity-Score-Weighted and -Matched Estimates in a Comparative Effectiveness Study: A Demonstration Using STAR*D Trial Data”. International Society for Pharmacoepidemiology (ISPE) 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, August 22-26, 2012.
  5. Farley JF, Maciejewski ML, Powers BJ, Sanders L, Farley JF, Hansen RA, Sleath B, Voils CI. “Implications of the continuity of medication management for the medical home of complex patients” Academy Health 2012 Annual Research Meeting, Orlando, FL, June 24-26, 2012.
  6. Wu CH, Farley JF, Gaynes BN. “The association between antidepressant dosage titration and medication adherence among patients with depression.” American Pharmacists Association Annual Meeting, New Orleans, LA, March 9-12, 2012.


  • Academy of Managed Care Pharmacy
  • American Association of Colleges of Pharmacy
  • Academy Health
  • American Pharmacists Association
  • International Society for Pharmacoeconomics and Outcomes Research



2014 – 2016, Chair Elect/Chair: Academy of Pharmaceutical Research and Science- Economic, Social, and Administrative Sciences Section

UNC Eshelman School of Pharmacy

  • Director, UNC/GSK Pharmaceutical Outcomes Research Postdoctoral Fellowship
  • Divisional Director of Graduate Studies (DDGS), Division of Pharmaceutical Outcomes and Policy, University of North Carolina, Eshelman School of Pharmacy
  • Graduate Education Committee, University of North Carolina, Eshelman School of Pharmacy


  • Medicaid Prescription Policy
  • Antipsychotic Medication
  • Outcomes Research
  • Pharmacoepidemiology
  • Pharmacy
  • Multiple Chronic Conditions